Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

77.63USD
7:15pm BST
Change (% chg)

$-0.62 (-0.79%)
Prev Close
$78.25
Open
$78.31
Day's High
$78.48
Day's Low
$77.30
Volume
503,640
Avg. Vol
1,509,024
52-wk High
$100.23
52-wk Low
$73.90

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Presents Updated Data From Mid-Stage Trial Of Empliciti Plus Pomalidomide And Dexamethasone In Multiple Myeloma
Friday, 14 Jun 2019 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PRESENTS UPDATED EFFICACY DATA FROM PHASE 2 TRIAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM).BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS - IN DESCRIPTIVE ANALYSIS, ADDITION OF EMPLICITI TO POMALIDOMIDE AND DEXAMETHASONE REDUCED RISK OF DEATH BY 46% AMONG PATIENTS WITH RRMM.BRISTOL-MYERS SQUIBB CO - SAFETY RESULTS FOR EPD WERE CONSISTENT WITH PRIMARY ANALYSIS AND WITH PRIOR FINDINGS FOR EMPLICITI AND POMALIDOMIDE REGIMENS.BRISTOL-MYERS SQUIBB - PATIENTS TREATED WITH EPD CONTINUED TO EXPERIENCE SUSTAINED & CLINICALLY RELEVANT OS AND PFS BENEFITS VERSUS PATIENTS TREATED WITH PD.  Full Article

AbbVie reaches agreement with pan-Canadian Pharmaceutical Alliance for Venclexta
Thursday, 23 May 2019 

May 23 (Reuters) - AbbVie Inc ::ABBVIE REACHES AN AGREEMENT WITH THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) FOR VENCLEXTA®, A TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).ABBVIE INC - FOLLOWING SIGNING OF AN AGREEMENT ONTARIO IS FIRST PROVINCE TO REIMBURSE VENCLEXTA..ABBVIE INC - VENCLEXTA MONOTHERAPY WILL BE AVAILABLE THROUGH EXCEPTIONAL ACCESS PROGRAM.  Full Article

Abbvie Launches Orilissa (Elagolix) 200 Mg Bid Dose For The Treatment Of Moderate To Severe Pain Associated With Endometriosis
Tuesday, 21 May 2019 

May 21 (Reuters) - AbbVie Inc ::ABBVIE LAUNCHES ORILISSA (ELAGOLIX) 200 MG BID DOSE FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS.ABBVIE INC - 7 OUT OF 10 WOMEN BEING MANAGED FOR ENDOMETRIOSIS HAVE UNRESOLVED PAIN THROUGHOUT MONTH.ABBVIE INC - ORILISSA (ELAGOLIX) 200 MG TWICE DAILY IS NOW AVAILABLE.  Full Article

Abbvie Provides Update On Depatuxizumab Mafodotin (Depatux-M)
Friday, 17 May 2019 

May 17 (Reuters) - AbbVie Inc ::ABBVIE PROVIDES UPDATE ON DEPATUXIZUMAB MAFODOTIN (DEPATUX-M), AN INVESTIGATIONAL MEDICINE FOR NEWLY DIAGNOSED GLIOBLASTOMA, AN AGGRESSIVE FORM OF BRAIN CANCER.ABBVIE INC - PHASE 3 INTELLANCE-1 STUDY, CONDUCTED IN COLLABORATION WITH RTOG FOUNDATION, DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL.ABBVIE INC - PHASE 3 INTELLANCE-1 STUDY DEMONSTRATED NO SURVIVAL BENEFIT FOR PATIENTS RECEIVING DEPATUX-M.ABBVIE - INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR INTERIM ANALYSIS DATA REVIEW RECOMMENDED STOPPING STUDY DUE TO LACK OF SURVIVAL BENEFIT.ABBVIE INC - ENROLLMENT IN ALL ONGOING DEPATUX-M STUDIES HAS BEEN HALTED.ABBVIE INC - NO NEW SAFETY FINDINGS WERE OBSERVED ON DEPATUXIZUMAB MAFODOTIN.  Full Article

AbbVie Says European Commission Approves Plaque Psoriasis Drug Skyrizi
Tuesday, 30 Apr 2019 

April 30 (Reuters) - AbbVie Inc ::EUROPEAN COMMISSION APPROVES SKYRIZI™ (RISANKIZUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.ABBVIE INC - APPROVAL ALLOWS FOR MARKETING OF SKYRIZI IN ALL MEMBER STATES OF EUROPEAN UNION, AS WELL AS ICELAND, LIECHTENSTEIN AND NORWAY.  Full Article

AbbVie Expects To See Humira Growth In Psoriasis Slow As Skyrizi Starts To Ramp Up
Thursday, 25 Apr 2019 

April 25 (Reuters) - AbbVie Inc ::ABBVIE SAYS EXPECTS SKYRIZI TO CONTRIBUTE ABOUT $150 MILLION IN 2019 SALES MAINLY IN SECOND HALF OF THE YEAR - CONF. CALL.ABBVIE SAYS EXPECTS FOREIGN EXCHANGE TO HAVE ABOUT 1 PERCENT UNFAVORABLE IMPACT ON FULL YEAR REPORTED SALES GROWTH - CONF. CALL.ABBVIE EXPECTS TO SEE HUMIRA GROWTH SLOW IN PSORIASIS CATEGORY AS SKYRIZI SALES STARTS TO RAMP SIGNIFICANTLY - CONF. CALL.ABBVIE SAYS HUMIRA BIOSIMILARS FROM BIOGEN AND AMGEN IN EUROPE HAVE BEEN THE MOST AGGRESSIVE IN THE MARKET SO FAR- CONF. CALL.ABBVIE SAYS CONSIDERING PUBLICIZING ITS DRUG ASSISTANCE PROGRAMS AS IT IS CONCERNED ABOUT MEDICARE PART D PATIENTS, WHO HAVE A "PRETTY SIGNIFICANT BURDEN" WITH OUT OF POCKET EXPENSES - CONF. CALL.ABBVIE SAYS IT IS INDUSTRY'S RESPONSIBILITY TO COVER SOME DRUG COSTS AND SHARE THEM WITH THE GOVERNMENT TO MAKE THEM AFFORDABLE FOR PATIENTS - CONF. CALL.  Full Article

Abbvie Announces First Regulatory Approval Of SKYRIZI
Tuesday, 26 Mar 2019 

March 26 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES FIRST REGULATORY APPROVAL OF SKYRIZI™ (RISANKIZUMAB) FOR THE TREATMENT OF PLAQUE PSORIASIS, GENERALIZED PUSTULAR PSORIASIS AND ERYTHRODERMIC PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN.ABBVIE INC SAYS JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED SKYRIZI AN INTERLEUKIN-23 INHIBITOR.  Full Article

AbbVie Says FDA Placed A Partial Clinical Hold On All Clinical Trials Evaluating Venetoclax For Investigational Treatment Of Multiple Myeloma
Tuesday, 19 Mar 2019 

March 19 (Reuters) - AbbVie Inc ::ABBVIE PROVIDES UPDATE ON VENCLEXTA®/VENCLYXTO® (VENETOCLAX) MULTIPLE MYELOMA PROGRAM.ABBVIE INC - FDA HAS PLACED A PARTIAL CLINICAL HOLD ON ALL CLINICAL TRIALS EVALUATING VENETOCLAX FOR INVESTIGATIONAL TREATMENT OF MULTIPLE MYELOMA.ABBVIE INC - PARTIAL CLINICAL HOLD FOLLOWS A REVIEW OF DATA FROM ONGOING PHASE 3 BELLINI TRIAL (M14-031).ABBVIE INC - TUESDAY'S ACTION DOES NOT IMPACT ANY OF APPROVED INDICATIONS FOR VENETOCLAX.ABBVIE - PATIENTS WHO ARE CURRENTLY ENROLLED IN STUDIES AND RECEIVING BENEFIT FROM THERAPY MAY CONTINUE WITH TREATMENT, AFTER CONSULTATION WITH PHYSICIAN.ABBVIE INC - INFORMED CLINICAL TRIAL INVESTIGATORS INVOLVED IN STUDIES OF RESULTS AND WILL WORK WITH THEM TO PROCEED AS APPROPRIATE.ABBVIE - A HIGHER PROPORTION OF DEATHS WAS OBSERVED IN VENETOCLAX ARM COMPARED TO CONTROL ARM OF TRIAL IN PHASE 3 BELLINI TRIAL (M14-031).  Full Article

Abbvie Receives CHMP Positive Opinion For Risankizumab For The Treatment Of Moderate To Severe Plaque Psoriasis
Friday, 1 Mar 2019 

March 1 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES CHMP POSITIVE OPINION FOR RISANKIZUMAB (SKYRIZI™) FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.ABBVIE - CHMP POSITIVE OPINION FOR RISANKIZUMAB FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

AbbVie Sets Quarterly Cash Dividend Of $1.07 Per Share
Thursday, 21 Feb 2019 

Feb 21 (Reuters) - AbbVie Inc ::SETS QUARTERLY CASH DIVIDEND OF $1.07PER SHARE.  Full Article

BRIEF-Abbvie Presents Data From Venetoclax Chemotherapy-Free Combination Regimen For Patients With Previously Untreated Chronic Lymphocytic Leukemia

* ABBVIE PRESENTS DATA FROM VENETOCLAX CHEMOTHERAPY-FREE COMBINATION REGIMEN FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA